Fluorine (F-18) floretyrosine Expanded Access Program (EAP)

Recruiting

99 years or below

All

Phase N/A

10 participants needed

Brief description of study

Primary Objective
The primary objective of this EAP is to enable the use of 18F-Floretyrosine with PET imaging to non-invasively detect tumor burden and/or treatment-related change to assist in the optimal management of patients with glioma. Secondary Objectives
The secondary objective of this EAP is to further confirm the safety and tolerability of 18F-Floretyrosine in patients with glioma(s). Differentiation between pseudoprogression and true Progression Intended management changes between Investigator Survey Questionnaire #1 and #2 represent the impact of imaging findings resulting in intended management changes. The categorization of the management change (major/minor) will be done by the participating site/Investigator and be part of data review plan.

Eligibility of study

You may be eligible for this study if you meet the following criteria:

Conditions: Medical Research
Age: 99 years or below
Gender: All

TBD

Updated on 16 Dec 2024. Study ID: 857188

You have contacted , on

Your message has been sent to the study team at ,

A copy of the message has been sent to your email

What happens next?

You can expect the study team to contact you via email or phone in the next few days.
Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

By sending a message, I agree that my data will be sent to a representative for the selected site and processed in accordance with this website's Privacy Policy (see link in footer).